<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Incidence of the esophagus <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> has been dramatically increasing in Western countries since the last decade </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0002020'>Gastroesophageal reflux disease</z:hpo> and <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> are risk factors for <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="25297">Methylenetetrahydrofolate</z:chebi> reductase (MTHFR) genes play a key role not only in <z:chebi fb="3" ids="37445">folate</z:chebi> metabolism but also in esophagus, stomach, pancreatic <z:mp ids='MP_0002038'>carcinoma</z:mp>, and <z:hpo ids='HP_0002488'>acute leukemias</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Studies have suggested that genetic polymorphisms of MTHFR (C677T) may clarify the causes and events involved in esophageal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In this study, we evaluated MTHFR C677T and A1298C polymorphisms, and <z:chebi fb="9" ids="17439">vitamin B12</z:chebi>, <z:chebi fb="3" ids="37445">folate</z:chebi>, and plasma homocystein levels in patients with esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (EAC), <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BE), <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0100633'>esophagitis</z:hpo>, and healthy controls (n = 26, n = 14, n = 30, and n = 30, respectively) </plain></SENT>
<SENT sid="5" pm="."><plain>The mean age of patients in the EAC and BE groups was significantly higher compared with the control group (P &lt; 0.001, P = 0.003, respectively) </plain></SENT>
<SENT sid="6" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> patient groups, serum <z:chebi fb="3" ids="37445">folate</z:chebi> levels were significantly lower than that of the control group (P &lt; 0.01, P &lt; 0.05, and P &lt; 0.01, respectively) </plain></SENT>
<SENT sid="7" pm="."><plain>There was no statistically significant association between <z:chebi fb="3" ids="37445">folate</z:chebi> levels and MTHFR gene polymorphisms </plain></SENT>
<SENT sid="8" pm="."><plain>No differences were found in terms of MTHFR gene polymorphisms, homocystein, and <z:chebi fb="13" ids="33611">B12</z:chebi> levels among the groups </plain></SENT>
<SENT sid="9" pm="."><plain>MTHFR gene polymorphisms and <z:chebi fb="3" ids="37445">folate</z:chebi> deficiency are not predictors of early <z:hpo ids='HP_0011459'>esophageal carcinoma</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>However, further studies using larger series of patients are needed to evaluate the effect of genetic polymorphisms in the <z:chebi fb="3" ids="37445">folate</z:chebi> metabolic pathway and to clarify the role of <z:chebi fb="3" ids="37445">folate</z:chebi> deficiency and <z:chebi fb="3" ids="37445">folate</z:chebi> metabolism in the development of esophagus <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
</text></document>